Page last updated: 2024-12-04

acridone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Acridone is a heterocyclic compound with a tricyclic structure containing a nitrogen atom. It serves as a core structure for a wide range of natural and synthetic compounds. Acridone derivatives exhibit diverse biological activities, including anti-cancer, anti-microbial, and anti-inflammatory properties. Research into acridone focuses on its potential therapeutic applications. Acridone can be synthesized through various methods, including the condensation of anthranilic acid with aromatic aldehydes. Studies explore the structure-activity relationship of acridone derivatives to optimize their therapeutic potential. Its importance stems from its versatile pharmacological properties and potential for developing novel drugs.'

acridone : A member of the class of acridines that is 9,10-dihydroacridine substituted by an oxo group at position 9. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2015
CHEMBL ID436589
CHEBI ID50756
SCHEMBL ID19289
MeSH IDM0122554

Synonyms (74)

Synonym
5-21-09-00007 (beilstein handbook reference)
unii-6bk306guqa
6bk306guqa ,
ccris 3317
ai3-00868
brn 0007104
acridine, 9,10-dihydro-9-oxo-
7h-dibenz(a,j)acrid-14-one
acridin-9-one
einecs 209-434-7
nsc 408196
9,10-dihydroacridin-9-one
nsc138672
nsc-138672
9-acridinol
643-62-9
MLS000551242 ,
smr000112235
nsc-7664
nsc7664
AE-641/00183032
9-acridanone
9(10h)-acridone
nsc408196
acridanone
9(10h)-acridinone
578-95-0
acridone
nsc-408196
acridine,10-dihydro-9-oxo-
9-acridone
9,10-dihydro-9-oxoacridine
CHEBI:50756 ,
acridin-9(10h)-one
inchi=1/c13h9no/c15-13-9-5-1-3-7-11(9)14-12-8-4-2-6-10(12)13/h1-8h,(h,14,15
9(10h)-acridanone, 99%
A0133
CHEMBL436589
10h-acridin-9-one
AKOS002257157
STK803038
AKOS000119816
NCGC00246256-01
C20142
HMS2271C03
FT-0621579
AB00572676-08
SCHEMBL19289
cid_2015
bdbm74759
Z57205009
DTXSID8060371
9-hydroxyacridine
9(10h)-acridanone
9(10h) acridone
9-(10h)acridone
9(10h)acridone
W-105430
9,l0-dihydro-9-oxoacridine
mfcd00005019
CS-W007771
9(10)h-acridone
F0486-2424
SY035720
9-acridone acridanone acridin-9-one acridine, 9,10-dihydro-9-oxo- dihydroketoacridine
BCP25846
Q342721
AS-17382
7h-dibenz[a,j]acrid-14-one
EN300-18139
mfcd00127712
acridoneacridone
HY-W007771
acridin-9-ol

Research Excerpts

Effects

Acridone has substantial bio-potential since it possess crucial activities such as antibacterial, antimalarial, antiviral and anti-neoplastic. The acridone formation has been further characterized in vitro using an enzyme-enriched fraction where activity per milligram protein is increased approximately 10-fold compared with the cytosolic fraction.

ExcerptReferenceRelevance
"Acridone scaffold has substantial bio-potential since it possess crucial activities such as antibacterial, antimalarial, antiviral and anti-neoplastic."( Acridone-based antitumor agents: a mini-review.
Alwan, WS; Amritkar, AA; Karpoormath, R; Mahajan, AA; Naphade, SS; Rane, RA; Yerigiri, MC, 2015
)
2.58
"The acridone formation has been further characterized in vitro using an enzyme-enriched fraction where activity per milligram protein is increased approximately 10-fold compared with the cytosolic fraction."( Inhibition by SKF-525A of the aldehyde oxidase-mediated metabolism of the experimental antitumour agent acridine carboxamide.
Bland, TJ; Robertson, IG, 1993
)
0.77
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
acridines
cyclic ketone
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (25)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency19.95260.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency28.18385.623417.292931.6228AID485281
Chain A, CruzipainTrypanosoma cruziPotency31.62280.002014.677939.8107AID1476
thioredoxin reductaseRattus norvegicus (Norway rat)Potency56.60720.100020.879379.4328AID588453; AID588456
TDP1 proteinHomo sapiens (human)Potency12.27980.000811.382244.6684AID686978; AID686979
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency25.11890.011212.4002100.0000AID1030
glucocerebrosidaseHomo sapiens (human)Potency25.11890.01268.156944.6684AID2101
alpha-galactosidaseHomo sapiens (human)Potency29.90334.466818.391635.4813AID1467; AID2107
serine-protein kinase ATM isoform aHomo sapiens (human)Potency17.78280.707925.111941.2351AID485349
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency38.36760.036619.637650.1187AID1466; AID2112; AID2242
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency35.48130.001815.663839.8107AID894
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency31.62283.548119.542744.6684AID743266
huntingtin isoform 2Homo sapiens (human)Potency35.48130.000618.41981,122.0200AID1688
importin subunit beta-1 isoform 1Homo sapiens (human)Potency44.66845.804836.130665.1308AID540263
snurportin-1Homo sapiens (human)Potency44.66845.804836.130665.1308AID540263
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency11.55750.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency11.00950.004611.374133.4983AID624296; AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency28.18380.125912.234435.4813AID1458
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency15.84890.00419.962528.1838AID2675
lamin isoform A-delta10Homo sapiens (human)Potency31.62280.891312.067628.1838AID1487
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency39.81073.548118.039535.4813AID1466
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Potency39.81073.548118.039535.4813AID1466
TAR DNA-binding protein 43Homo sapiens (human)Potency39.81071.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
karyopherin alpha 2 (RAG cohort 1, importin alpha 1), isoform CRA_bHomo sapiens (human)EC50 (µMol)49.12000.918141.9368121.5000AID435026
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glycogen synthase kinase-3 alphaHomo sapiens (human)AC50300.00000.013529.7434171.7000AID463203
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (18)

Processvia Protein(s)Taxonomy
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (33)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID538296Cytotoxicity against human HaCaT cells assessed as LDH release at 2 uM after 4 hrs by UV method2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Structure-activity relationship studies of acridones as potential antipsoriatic agents. 2. Synthesis and antiproliferative activity of 10-substituted hydroxy-10H-acridin-9-ones against human keratinocyte growth.
AID538298Antioxidant activity assessed as DPPH free radical scavenging activity2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Structure-activity relationship studies of acridones as potential antipsoriatic agents. 2. Synthesis and antiproliferative activity of 10-substituted hydroxy-10H-acridin-9-ones against human keratinocyte growth.
AID1640018Luciferase/luciferin-expressing antifolate-resistant parasites were used to infect a culture of HepG2 cells that were pre-incubated with compounds. Infected hepatocytes emit light due to the luciferase reaction. Assay results are presented as the percent 2018Science (New York, N.Y.), 12-07, Volume: 362, Issue:6419
Open-source discovery of chemical leads for next-generation chemoprotective antimalarials.
AID55500Concentration required to give 50% fluorescence quenching of bound ethidium for [ethidium]: [poly(dA-dT)]2 DNA in ratio of 0.1:1 at pH 51997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID46169Inhibitory concentration against ethidium:Calf thymus DNA(0.1:1) binding at pH 51997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID605707Inhibition of heme-mediated bovine serum albumin oxidation assessed as protein carbonyl formation after 1 hr in presence of H2O2 at pH 7.42011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Synthesis of novel heme-interacting acridone derivatives to prevent free heme-mediated protein oxidation and degradation.
AID202961Cytotoxic potency required to inhibit SKOV-3 cell growth 50%1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID605705Binding affinity to heme assessed as equilibrium binding constant by UV-visible spectrophotometry2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Synthesis of novel heme-interacting acridone derivatives to prevent free heme-mediated protein oxidation and degradation.
AID98563Cytotoxic potency required to inhibit L1210 cell growth by 50% after cell drug contact for 48 hrs1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID55499Concentration required to give 50% fluorescence quenching of bound ethidium for [ethidium]: [(poly dG-dC)]2 DNA in ratio of 0.1:1 at pH 51997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID673777Cytotoxicity in UV-irradiated human U937 cells exposed to photosensitizer for 2 hrs before irradiation for 20 mins by WST-1 assay2012ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4
Type 1 Phototherapeutic Agents. 2. Cancer Cell Viability and ESR Studies of Tricyclic Diarylamines.
AID46137Inhibitory concentration against ethidium:Calf thymus DNA(1.26:1) binding at pH 7; Measurement not possible due to ligand fluorescence1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID1640019Luciferase/luciferin-expressing antifolate-resistant parasites were used to infect a culture of HepG2 cells that were pre-incubated with compounds. Infected hepatocytes emit light due to the luciferase reaction. Assay results are presented as the percent 2018Science (New York, N.Y.), 12-07, Volume: 362, Issue:6419
Open-source discovery of chemical leads for next-generation chemoprotective antimalarials.
AID47499Cytotoxic potency required to inhibit CH1 cell growth by 50%1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID538295Antiproliferative activity against human HaCaT cells assessed as dispersed cells after 48 hrs by phase-contrast microscopic analysis2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Structure-activity relationship studies of acridones as potential antipsoriatic agents. 2. Synthesis and antiproliferative activity of 10-substituted hydroxy-10H-acridin-9-ones against human keratinocyte growth.
AID72412Cytotoxic potency required to inhibit G-361 cell growth by 50%1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID387035Antiproliferative activity against human CCRF-CEM cells after 48 hrs by MTT assay2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Synthesis and potent antileukemic activities of 10-benzyl-9(10H)-acridinones.
AID46134Inhibitory concentration against ethidium:Calf thymus DNA (1.26:1) at pH 5; Measurement not possible due to ligand fluorescence1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID10007Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID249256Partition coefficient (logP) of the compound2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Extravascular transport of drugs in tumor tissue: effect of lipophilicity on diffusion of tirapazamine analogues in multicellular layer cultures.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (152)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (3.29)18.7374
1990's17 (11.18)18.2507
2000's60 (39.47)29.6817
2010's58 (38.16)24.3611
2020's12 (7.89)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 53.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index53.67 (24.57)
Research Supply Index5.06 (2.92)
Research Growth Index5.14 (4.65)
Search Engine Demand Index87.16 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (53.67)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.65%)5.53%
Reviews17 (10.97%)6.00%
Case Studies1 (0.65%)4.05%
Observational0 (0.00%)0.25%
Other136 (87.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]